Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy

Cardiovascular Drugs and Therapy
H BricaudJ Bonnet

Abstract

The aim of this study was to assess the value of long-term treatment with 60 mg per day of trimetazidine, a cellular antiischemic agent, in comparison with placebo, in patients with ischemic cardiomyopathy controlled by conventional treatments. Twenty patients, with a mean age of 59.5 +/- 1.6 years, suffering from severe ischemic cardiomyopathy (NYHA IV, 6 patients; NYHA III, 14 patients) confirmed by coronary angiography, were included in the study; four of them suffered from residual angina. All of these patients were receiving long-term treatment with long-acting nitrates associated with digitalis (9 patients), diuretics (15 patients), anticoagulants (13 patients), and antiarrhythmics (11 patients), and were considered to be stabilized at the time of inclusion in the study. The examinations consisted of clinical and laboratory assessment, resting ECG, 24-hour ECG monitoring, X-ray evaluation of cardiac volume (CV), and evaluation of echocardiographic left ventricular shortening (ELVS) and of isotopic ejection fraction (EF). These three parameters were expressed as a percentage variation with respect to the initial value, and their variation between the two groups was compared by means of two-way analysis of variance. Clinica...Continue Reading

References

Aug 1, 1985·British Journal of Clinical Pharmacology·I Maridonneau-Parini, C Harpey
Mar 1, 1988·Cardiovascular Drugs and Therapy·J F Renaud
Jan 1, 1987·European Journal of Clinical Pharmacology·P SellierP Ourbak

❮ Previous
Next ❯

Citations

Jan 1, 1997·Fundamental & Clinical Pharmacology·E FantiniA Grynberg
Feb 25, 2006·The Tohoku Journal of Experimental Medicine·Filiz KuralayOzhan Goldeli
Aug 29, 2013·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Jeong Su KimMyung Ho Jeong
Apr 4, 2006·Journal of Electrocardiology·Ergun TopalSengül Cehreli
Aug 9, 2016·Cardiovascular Drugs and Therapy·Giacinta GuariniMario Marzilli
Jan 15, 2014·Journal of Cardiac Failure·José Luis WinterSergio Lavandero
Sep 21, 2001·Fundamental & Clinical Pharmacology·E SentexA Grynberg
Feb 28, 2008·Physiological Genomics·Georges E HaddadJudith K Gwathmey
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Imène Tabbi-AnneniAlain Grynberg
Jan 31, 2019·European Cardiology·Giacinta GuariniMario Marzilli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.

Related Papers

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Evgeniy V ShlyakhtoNatalya V Vakhrameyeva
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie
F GirginT Tanyalcin
© 2021 Meta ULC. All rights reserved